wimike, on the off chance that you’re being sincere, I’ll respond since it may also help others as well. You’re correct that investing in biotech is risky, and it sounds like you were unprepared for how long it can take a small company to develop a cell therapy treatment. However, much of the type of risk that you’ll find investing in other developmental biotechs, has been mitigated in NWBO, because positive results of the clinical trial have been published, and additional information that is necessary for commercial approval has been presented.
You were smart enough to find Northwest Bio in the first place, and strong enough in your conviction to make an investment, so don’t allow the current price to discourage you now. NWBO trades on the OTC market, where very large institutional investors, who buy very large quantities of stock, (in the millions) can not invest, so buying is left mostly to small retail investors, who are only able to buy a relatively small number of shares. Therefore, the true demand for shares may not be accurately reflected on the OTC market. This light buying volume allows the price to be controlled and suppressed by some deep-pocketed hedge funds, who have motives other than seeing the company succeed, and the stock price rise. These entities want to create Fear, Uncertainty, and Doubt to scare novice investors into selling their stock far below the true value, so that these entities can make the profit rather than the novice investor. The true value of the company, which is actually much, much higher than the current price, should be reflected in the stock price one day soon, but that may not occur until Northwest Bio is able to uplist off the OTC market, and institutional investors are able to buy NWBO.
And by the way, a couple of other cell therapy companies were purchased right before regulatory approval for $10B and $12B, and the market they were approved for, was a much smaller market than Glioblastoma. Northwest Bio should be worth well north of those two companies, so no, the days of hoping for a higher price have definitely not “left the building.”
